Globalpharma and ZIM Labs Partner to Advance Oral Drug Tech in UAE

Globalpharma, a premier pharmaceutical manufacturer in the UAE and a subsidiary fully owned by Dubai Investments PJSC, has announced a strategic partnership with India’s ZIM Laboratories. This collaboration introduces Oral Dispersible Film (ODF) technology—certified under the European Union's Good Manufacturing Practice (EU-GMP)—to Globalpharma’s expanding product line, ensuring international standards of safety and quality.

Spotlight on Innovation at AIM Congress 2025

The partnership was formally introduced during AIM Congress 2025, held from April 7 to 9. This move emphasizes the UAE's growing presence in the global pharmaceutical landscape and its dedication to adopting next-generation healthcare technologies.

High-Profile Signing Ceremony with Industry Leaders

The agreement was officially signed by Mohammed Saeed Al Raqbani—General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma—and Zulfiquar Kamal, Promoter and Finance Director of ZIM Labs. The signing was attended by key dignitaries, including H.E. Dr. Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Board of Emirates Drug Establishment (EDE), along with Dr. Mariam Galadari, a Board Member at Globalpharma.

Globalpharma’s Vision Showcased on the Global Stage

Further underlining its role as an industry leader, Globalpharma’s General Manager, Dr. Basem Al-Barahmeh, delivered an insightful keynote at AIM Congress 2025. He highlighted the UAE’s rise as a global center for pharmaceutical manufacturing. Meanwhile, Dr. Geeta Gujaran, Site Head at Globalpharma, contributed to the “Leaders' Panel: Manufacturing 2030,” offering expert perspectives on the transformative trends shaping the pharmaceutical industry’s future.

Commenting on the collaboration, Mohammed Saeed Al Raqbani stated: “This partnership with ZIM Labs is a transformative step for Globalpharma. By bringing EU-certified ODF technology to the UAE, we are strengthening the region’s pharmaceutical capabilities and advancing patient-centric treatment options. This move aligns with our vision to invest in innovations that elevate regional healthcare standards while positioning the UAE as a leader in advanced drug manufacturing.”

Oral Dispersible Films: Redefining Patient-Centric Medication

ODFs are an innovative drug delivery system comprising ultra-thin films that dissolve instantly on the tongue—requiring no water. This makes them particularly suitable for children, elderly individuals, and patients who struggle with traditional tablets. Powered by ZIM Labs' proprietary formulation techniques, these films allow for effective, stable, and rapid drug absorption—enhancing treatment outcomes and patient adherence.

Globalpharma’s General Manager, Dr. Basem Al-Barahmeh, emphasized the significance of this development: “By acquiring and localizing ODF production within UAE facility, Globalpharma is not only introducing innovative treatments but also setting a benchmark for pharmaceutical manufacturing in the region. Our dedicated production line, with a growing portfolio of ten ODF products, puts us at the forefront of this technology in the Middle East. This step reinforces the UAE’s role as a key player in global pharma advancements.”

Zulfiquar Kamal, Promoter & Finance Director at ZIM Labs, also highlighted the collaboration’s impact: “This technology transfer with globalpharma is a significant milestone in our mission to expand access to patient-friendly drug delivery systems around the world. Our EU-GMP certified ODF technology, combined with Globalpharma's regional reach and manufacturing strength, will set a new benchmark for pharmaceutical innovation in the GCC."

ZIM Laboratories: Pioneering Drug Delivery Solutions

ZIM Laboratories Limited is a research-led pharmaceutical enterprise focused on creating differentiated oral solid dosage forms across various therapeutic areas. With advanced in-house R&D facilities, ZIM Labs develops innovative solutions designed to improve patient convenience and treatment compliance. The company is publicly listed on both the National Stock Exchange of India (NSE) and BSE Limited, marking its presence in the global pharmaceutical market.